The Muscle Mag
The company is presenting its new range at CPHI Milan, featuring three pectin-based products: GummiBiotics Defense, GummiBiotics IBS Ease, and GummiBiotics Lean. These products contain ingredients like EpiCor postbiotic and DE111 probiotic.
“At Sirio, we are proud of our R&D capabilities and invest a significant portion of our earnings in them. Our technical and formulation teams make up 13% of our total employee base, which is unique for a CDMO,” said Sara Lesina, general manager of Sirio Europe & Americas.
“We work closely with our customers and experts to create innovative products that lead the market. The launch of the new GummiBiotics range demonstrates our commitment to partnering with top ingredient suppliers to deliver science-backed biotics in delicious gummy form,” she added.
A growing market
The biotic supplement segment accounts for a significant portion of all supplements sold, according to Sirio’s press release.
Probiotics remain a leading subcategory under biotics. In the EU, the probiotic supplement market was valued at US$1.7 billion in 2023 and is projected to grow at a rate of 7% from 2021 to 2024, as reported by Euromonitor in 2024.
The global gummy market is also experiencing significant growth, with an average CAGR of 14% since 2020. By 2025, the European gummy market is expected to grow by over 50% from around $240 million in 2022 to nearly $385 million in 2025.
Details
GummiBiotics Defense contains 500 mg of EpiCor postbiotic per serving, along with 5 mg of zinc to support the immune system.
GummiBiotics IBS Ease features ADM’s ES1 Postbiotic, which has been shown to help manage symptoms of IBS-D and reduce occasional diarrhea in clinical studies. The gummy also includes prebiotic xylo-oligosaccharides and calcium.
GummiBiotics Lean is formulated with 500 mg of apple cider vinegar, vitamin B6, and 5 billion CFU of DE111 (Bacillus subtilis) probiotic per serving.
